just my opinion, I think everyone has one eye on us for sure. our studies are a double edged sword. we have chosen patients that are so sick they wouldn't meet the grade for US studies. ballsy and very impressive, yes. flip side is until we see technical data, we don't know what the %'s mean. the study I referred to had an average base line of 295 meters and on "healthier" patients which general fitness could be argued less variable for improvement. then again, that may be the complete opposite and our results are better than what we read. we won't know until the technical data is released. this doesn't diminish our announcement, it's fantastic every way you read it.
IMHO the big boys are attentively observing and will be looking for the technical data at 12 months on all the trial patients, plus the FDA trial etc. a simple reason for this is at 12 months both valves had a patient slight decline in 6MWT. any stability or improvement at 12 months IMO would put us in a very powerful position.
GLTAL
AVR Price at posting:
$22.77 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)